Cash Flow Statement (Annual)

HRS / Harris Corp. Short Interest

HRS / Harris Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss 561,600 588,000 30,600 113,000 534,800 334,000 324,000 -
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization 165,700 212,000 260,300 220,600 204,300 233,000 229,000 183,000
    Amortization Of Intangible Assets From Acquisition - - - - 0 11,000 132,000 128,000
    Share Based Compensation 35,300 46,100 34,700 32,900 35,400 37,000 39,000 42,000
    Pension Contributions - - - - 0 1,000 174,000 589,000
    Pension Expense Reversal Of Expense Noncash - - - - - -1,000 -26,000 -97,000
    Asset Impairment Charges - - - - 0 46,000 367,000 240,000
    Gain Loss On Sale Of Business - - - - - 9,000 10,000 -14,000
    Increase Decrease In Operating Assets
      Increase Decrease In Accounts Receivable - - - - - - - -
      Increase Decrease In Inventories 13,900 64,700 25,200 54,100 -50,100 -20,000 28,000 -28,000
    Increase Decrease In Operating Liabilities
      Increase Decrease In Accounts Payable - - - - - - - -
      Increase Decrease In Customer Advances 53,000 47,600 23,800 82,500 -42,000 -48,000 -96,000 -42,000
      Increase Decrease In Income Taxes - - - - - -2,000 199,000 131,000
      Increase Decrease In Other Operating Capital Net -18,500 15,100 1,000 -10,000 52,400 -65,000 -111,000 151,000
  Net Cash Provided By Used In Operating Activities 802,700 833,100 852,900 833,000 849,200 854,000 924,000 569,000
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 189,900 311,300 209,900 164,800 209,300 148,000 152,000 119,000
  Proceeds From Divestiture Of Businesses - 0 0 147,400 42,000 50,000 181,000 1,014,000
  Adjustmentsto Proceeds From Saleof Business - - - - 0 0 11,000 25,000
  Net Cash Provided By Used In Investing Activities -250,100 -1,417,500 -248,900 -19,700 -162,600 -3,284,000 -1,000 870,000
Net Cash Provided By Used In Financing Activities
  Proceeds From Borrowings 0 852,100 9,400 18,200 34,200 3,683,000 61,000 85,000
  Repayments Of Unsecured Debt - - - - - 954,000 730,000 584,000
  Proceeds From Stock Options Exercised 18,900 24,500 28,200 97,900 141,300 47,000 44,000 54,000
  Payments For Repurchase Of Common Stock 208,000 256,100 473,500 414,900 309,400 150,000 0 710,000
  Payments Of Dividends Common Stock 115,000 127,000 139,600 164,700 180,300 198,000 252,000 262,000
  Proceeds From Payments For Other Financing Activities - - - - -9,000 -55,000 -16,000 -21,000
  Net Cash Provided By Used In Financing Activities -380,900 492,800 -609,800 -839,700 -448,100 2,373,000 -893,000 -1,438,000
Effect Of Exchange Rate On Cash And Cash Equivalents 2,300 3,300 -5,100 -8,600 1,500 -23,000 -24,000 -4,000
Cash And Cash Equivalents Period Increase Decrease 174,000 -88,300 -10,900 -35,000 240,000 -80,000 6,000 -3,000
Cash And Cash Equivalents At Carrying Value - - 356,000 321,000 561,000 481,000 487,000 484,000

Peers - Search, Detection, Navigation, Guidance, Aeronautical, and Nautical Systems and Instruments (3812)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 413875105